Cost-effective analysis of sugemalimab plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma with PD-L1 CPS ≥5
From the perspective of China's healthcare system, SUG-CAP as first-line therapy for advanced G/GEJ adenocarcinoma with PD-L1 CPS ≥5 is not cost-effective compared with chemotherapy alone.
Authors
- Maojin You
- Yalan Zhang
- Ruijia Chen (ORCID: https://orcid.org/0000-0001-7614-7576)
- Ying He
Institutions
- Fujian Medical University (CN)
- Second Affiliated Hospital of Fujian Medical University (CN)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2025-08-22
- DOI
- https://doi.org/10.3389/fpubh.2025.1604372
- Citations
- 2
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Fujian Medical University